However, in vivo PD-1 targeting in B-ALL mice efficiently reduced disease burden and extended overall survival versus placebo-treated mice (p = 0.0177; Figure 4A–C and Figure S9). Here, PDCD1 is linked to acute lymphoblastic leukemia.